Matching-adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel; bb2121) from the KarMMa study vs selinexor plus dexamethasone (Sd; STORM part 2) and belantamab mafodotin (BM; DREAMM-2)-MedSci.cn

Matching-adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel; bb2121) from the KarMMa study vs selinexor plus dexamethasone (Sd; STORM part 2) and belantamab mafodotin (BM; DREAMM-2)

Weisel, K; Rodriguez-Otero, P; Davies, F; Delforge, M; Ayers, D; Cope, S; Jansen, JP; Mojebi, A; Hege, K; Dhanasiri, S

ONCOLOGY RESEARCH AND TREATMENT, 2020; 43 (SUPPL 4): 118

科室
- - 订阅+
  - 更多科室
工具
服务